CAR-T Cells: The Next Era in Immuno-Oncology | Page 4

An update on immunotherapies and the potential impact of chimeric antigen receptor (CAR)-T cells on oncology care.
Published Online: February 14, 2017
Bruce A. Feinberg, DO; Jennifer Fillman, MBA; Justin Simoncini, MBA, MPH; and Chadi Nabhan, MD, MBA, FACP
Although a number of the factors described will contribute to the commercial success of these compounds, including final label, pricing, and clinical data, the largest driver of market uptake may be timing to first approval and initial experience with a commercial product. Once approved, CAR-T therapy will likely continue the trend of I-O therapeutic success. On the heels of CTLA-4, PD-1, and PD-L1, activated cellular therapy in the form of CAR-T cells will further the transformation of systemic cancer care from a chemotherapy to an I-O platform. However, the expansion of I-O platforms across an increasing number of malignancies, their indication in earlier lines of treatment, the anticipated use of I-O in combination, and trial designs that treat until progression may quickly erode the enthusiasm over their clinical benefit as stakeholders become mired in the debate over their cost. 

Bruce A. Feinberg, DO, is vice president and chief medical officer, Cardinal Health Specialty Solutions, Cardinal Health.

Jennifer Fillman, MBA, is vice president and general manager, Specialty Services, Cardinal Health Specialy Solutions, Cardinal Health.

Justin Simoncini, MBA, MPH, is vice president for strategy, Cardinal Health Specialty Solutions, Cardinal Health.

Chadi Nabhan, MD, MBA, FACP, is vice president and chief medical officer, Cardinal Health Specialty Solutions, Cardinal Health.

Bruce Feinberg, DO
55 Lafayette Dr. NE
Atlanta, GA 30309
  1. Ledford H. Melanoma drug wins US approval. Nature. 2011;471(7340):561. doi: 10.1038/471561a.
  2. Poole RM. Pembrolizumab: first global approval. Drugs. 2014;74(16):1973-1981. doi: 10.1007/ s40265-014-0314-5.
  3. Kazandjian D, Suzman DL, Blumenthal G, et al. FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy. Oncologist. 2016;21(5):634-642. doi: 10.1634/theoncologist.2015-0507.
  4. Markham A. Atezolizumab: first global approval. Drugs. 2016;76(12):1227-1232. doi: 10.1007/ s40265-016-0618-8.
  5. Feinberg B. Where does immuno-oncology fit in a value-based care delivery model? Am J Manag Care. 2016;22(S2):SP40-SP41, SP46.
  6. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507-1517. doi: 10.1056/NEJMoa1407222.
  7. Almasbak H, Aarvak T, Vemuri MC. CAR T cell therapy: a game changer in cancer treatment. J Immunol Res. 2016;2016:5474602. doi: 10.1155/2016/5474602.
  8. Maude SL, Teachey DT, Porter DL, Grupp SA. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015;125(26):4017-4023. doi: 10.1182/ blood-2014-12-580068.
  9. van der Stegen SJ, Hamieh M, Sadelain M. The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov. 2015;14(7):499-509. doi:
  10. 1038/nrd4597. 10. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725-733. doi: 10.1056/NEJMoa1103849.
  11. Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373(16):1541-1552. doi: 10.1056/NEJMra1400972.
  12. Zugmaier G, Gokbuget N, Klinger M, et al. Long-term survival and T-cell kinetics in relapsed/ refractory ALL patients who achieved MRD response after blinatumomab treatment. Blood. 2015;126(24):2578-2584. doi: 10.1182/blood-2015-06-649111.
  13. Porter DL, Hwang WT, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7(303):303ra139. doi: 10.1126/scitranslmed.aac5415.
  14. Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540-549. doi: 10.1200/JCO.2014.56.2025.
  15. Turtle C, Berger C, Sommermeyer D, et al. Anti-CD19 chimeric antigen receptor-modified T-cell therapy for B-cell non-Hodgkin Lymphoma and chronic lymphocytic leukemia: fludarabine and cyclophosphamide lymphodepletion improves in vivo expansion and persistence of CAR-T cells and clinical outcomes. Blood. 2015;126:184.
  16. Schuster S, Svoboda J, Nasta S, et al. Sustained remissions following chimeric antigen receptor modified T Cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas. Blood. 2015;126:183.
  17. Neelapu S, Locke F, Bartlett N, et al. Kte-C19 (anti-CD19 CAR T Cells) induces complete remissions in patients with refractory diffuse large B-cell lymphoma (DLBCL): results from the pivotal phase 2 ZUMA-1. Presented at the 58th American Society of Hematology Annual Meeting & Exposition, December 6. Abstract LBA-6.
  18. Garfall AL, Stadtmauer EA, June CH. Chimeric Antigen Receptor T Cells in Myeloma. N Engl J Med. 2016;374(2):194. doi: 10.1056/NEJMc1512760.
  19. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509-1518. doi: 10.1056/NEJMoa1215134.
  20. Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra138. doi: 10.1126/scitranslmed.3005930.
  21. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra225. doi: 10.1126/scitranslmed.3008226.
  22. Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517-528. doi: 10.1016/S0140-6736(14)61403-3.
  23. Turtle C, Hanafi L, Berger C, et al. Addition of fludarabine to cyclophosphamide lymphodepletion improves in vivo expansion of CD19 Chimeric antigen receptor-modified T cells and clinical outcome in adults with B cell acute lymphoblastic leukemia. Blood. 2015;126:3773.
  24. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119(12):2709-2720. doi: 10.1182/ blood-2011-10-384388.
  25. Brentjens RJ, Riviere I, Park JH, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011;118(18):4817-4828. doi: 10.1182/blood-2011-04-348540.
  26. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188-195. doi: 10.1182/blood-2014-05-552729.
  27. Davila ML, Sadelain M. Biology and clinical application of CAR T cells for B cell malignancies. Int J Hematol. 2016;104(1):6-17. doi: 10.1007/s12185-016-2039-6.
  28. Grupp S, Laetsch T, Buechner J, et al. Analysis of a global registration trial of the efficacy and safety of CTL019 in Pediatric and young adults with relapsed/refractory acute lymphoblastic leukemia. Presented at: 58th American Society of Hematology Annual Meeting & Exposition; December 3. Abstract 221.
Adult ADHD Compendium
COPD Compendium
Dermatology Compendium
Diabetes Compendium
Hematology Compendium
Immuno-oncology Compendium
Lipids Compendium
MACRA Compendium
Neutropenia Compendium
Oncology Compendium
Pain Compendium
Reimbursement Compendium
Rheumatoid Arthritis Compendium
Know Your News
HF Compendium
Managed Care PODCAST